I've been thinking further about this valuation, whilst it...

I've been thinking further about this valuation, whilst it makes sense based on current financials for this to be priced at 50c to $1, the market is inevitably forward looking. The $28m run rate today is great, but the market will be looking even further ahead. It'll be thinking about the high probability of revenues in the hundreds of millions of dollars due to the massive interventional glaucoma trend taking place, and thus we could see a valuation well above $1 based on these fundamentals. Perhaps as high as $5 (after all, that's only a $1bn market cap)

It's very clear that this is significantly undervalued, how undervalued though is the question on all of our minds. The hard numbers don't lie, and when that profit is announced in the near future this should really explode (perhaps a DRO type rally - $2 billion market cap is a 40x gain from current prices). There's a lot of catching up that must be done share price wise to first price in everything that has happened over the past year and a bit, then we can begin to think about pricing in the future stuff